Guardant Health
Guardant Health, Pfizer Partner to Use Liquid Biopsy to Aid Cancer Therapy Development
Pfizer intends to use Guardant's blood-based tests in global clinical trials, with specific plans to evaluate the clinical utility of its Reveal assay as clinical trial surrogate endpoint.
A discussion at the Precision Medicine Tri-Con demonstrated that stakeholders are narrowing in on the challenges to realizing the promise of solid tumor MRD.
Guardant Health's Shield Colorectal Cancer Blood Test Garners CMS Advanced Diagnostic Status
The test will be reimbursed at the price of $1,495 for Medicare patients during the initial nine-month ADLT period starting on April 1.
In Brief This Week: Eisai, Biogen, Carsgen, VolitionRx, Ocugen, Regenxbio, Guardant Health, Avacta
News items for the week of March 3, 2025.
Focus on Primary Resistance May Improve KRAS Inhibitor Strategies in Colorectal, Pancreatic Cancer
Premium
The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.